CF PharmTech, Inc. filed a Next Day Disclosure Return on 11 May 2026 detailing an on-market buyback of 8,500 H-shares executed the same day. The shares were repurchased at prices between HKD 21.80 and HKD 22.00, translating to a volume-weighted average of HKD 21.93 and a total outlay of approximately HKD 0.19 million.

The transaction reduced the company’s issued share capital (excluding treasury shares) by 0.0028% to 301.52 million shares. Concurrently, the treasury-share balance increased from 0.70 million to 0.71 million, while the total number of issued shares remained unchanged at 302.22 million.

The buyback forms part of a mandate approved on 16 December 2025 that authorises repurchases of up to 30.22 million shares. To date, CF PharmTech has repurchased 707,500 shares under this mandate, utilising 0.23% of the authorised limit.

In line with Hong Kong listing rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 10 June 2026. Management confirmed that the repurchase complied with all applicable regulations and that all required approvals and filings are in place.